Piramal Healthcare has invested two million pounds (about Rs 20 crore) to expand its manufacturing plant in Scotland. The plant manufactures anti-cancer drugs (antibody drug conjugates) for export. This new investment into Scotland will yield additional revenue of 3-5 million pounds (about Rs 30-50 crore) over five years to Piramal Healthcare’s revenue. Piramal Healthcare has manufacturing plants in India, US, Canada and Scotland and contributes to about 60% of the Rs 5,000 crore group revenue in FY15.